Semeiotica Biofisica Quantistica. Il Nuovo Rinascimento della Medicina. www.sisbq.org

Articoli con tag ‘Oncological Terrain’

Sideri’s Sign in bedside Recognizing in one second Breast Cancer, even in initial Stage of Inherited Real Risk.

This clinical sign of Quantum Biophysical Semeiotics is dedicated to the greatest Italian Oncologist, Prof. Mario Sideri, Director, Preventive Gynecology Unit  Gynecology Division, European Institute of Oncology, Via G. Ripamonti 435.

In Memoriam

Sideri’s Sign.

Regarding whatever gene mutation,  it is necessary to remember, emphasising it, that all gene mutations bring about neessarily local biological activity modification, otherwise, gene mutations would be meaningless innocent bystanders (1-4).

Nowadays, physicians all around the world could fortunately utilize in both bedside detection and primary prevention of breast cancer (as well as in every malignancy, of course) some interesting paramount knowledges, mainly overlooked. Using breast cancer risk assessment tools (e.g., traditional breast physical examination, denaturing high performance liquid chromatography (DHPLC) to screen for mutations of BRCA1- BRCA-2, a.s.o.) and going through the process of assessing breast cancer risk by this sophysticated way, can answer many women’s questions about what puts them at relatively higher or lower risk (1, 3).

Certainly, such a evaluation is expensive for NHS, and not applicable for all women and men (!), of course, not to speak of the inability of both Laboratory and Image Department to recognize Breast Cancer Inherited Real Risk (3-14). In fact, for all healthy women and men, an original clinical assessement may be desirable, if capable in a easy, reliable, and no expensive manner  to allow doctor to bedside recognize the presence of maternally-inherited Oncological Terrain, and Breast Cancer Oncological Terrain-Dependent, Inherited Real Risk, based on the presence of a tipical microcirculatory remodelling of mamma microvessels, due to newborn-pathological, type I, subtype a) oncological,  Endoarterial Blocking Devices (1-9), conditio sine qua non of cancer (3, 11, 12).

In spite of genetic testing, bedside ascertaining particularly breast cancer Inherited Real Risk in well-defined breast quadrant(s) allows doctor  to perform quickly an efficient primary prevention of such a malignany. In addition, testing for mutations breast cancer susceptibility genes or for their diminished expression adds to our ability to assess breast cancer risk at an individual level, because local biological activity, examined with the aid of quantum biophysical semeiotics, results abnormal. Really, by the aid of sophysticated image department  we cannot localise in mamma quadrant(s) the possible breast cancer risk, in BRCA 1, or BRCA1 mutation, E1373X in exon 12. and BRCA 2 positive women (and men) (2, 8-20).

On the contrary,  Quantum Biophysical Semeiotics allows doctor to recognize clinically firstly Oncological Terrain in a quantitative way, and then, if present, of course, breast cancer heritable real risk: individuals with Oncological Terrain do not show necessarily also breast cancer INHERITED Real Risk (3-11) .

In health, the “Intense” and lasting  pintching of  skin of  whatever mamma point, due to the non-local Realm in biological systems (15-16), does not bring about simultaneously the mamma-gastric aspecific Reflex (= in the stomach, both fundus and body dilates, while antral-pyloric region contracts).

On the contrary, in case of breast cancer, even in its initial stage of Inherited Real Risk, under the same condition, illustrated above, the mamma-gastric aspecific Reflex appears “simultaneously”, immediately followed by the typical tonic gastric Contraction: Sideri’s Sign.

The intensity of reflex, measured in cm.,  parallels the seriousness of underlying disorders.   In presence of heritable real risk, the intensity of reflex is less than 1 cm.

References.
1. Stagnaro-Neri M., Stagnaro S., Cancro della mammella: prevenzione primaria e diagnosi precoce con la percussione ascoltata. Gazz. Med. It. – Arch. Sc. Med. 152, 447, 1995
2 Stagnaro Sergio. Biological System Functional Modification parallels Gene Mutation. http://www.Nature.com, March 13, 2008,http://blogs.nature.com/nm/spoonful/2008/03/gout_gene.html

3. Stagnaro-Neri M., Stagnaro S. Introduzione alla Semeiotica Biofisica. Il Terreno Oncologico. Travel Factory, Roma, 2004. http://www.travelfactory.it/semeiotica_biofisica.htm
4. Stagnaro S. Genes and Cancer: a clinical view-point. The Oncological Terrain. BioMed Central Informatics. http://www.biomedcentral.com/1471-2105/5/21/comments#10454
5. Stagnaro Sergio. Clinical tool reliable in bedside early recognizing pancreas tumour, both benign and malignant. World Journal of Surgical Oncology 2005, 3:62 doi:10.1186/1477-7819-3-62.
6. Stagnaro Sergio. “Genes, Oncological Terrain, and Breast Cancer” World Journal of Surgical Oncology., 2005, http://www.wjso.com/content/3/1/45/comments#205475
7. Stagnaro Sergio. Reale Rischio Semeiotico-Biofisico. Ruolo Diagnostico e Patogenetico dei Dispositivi Endoarteriolari di Blocco neoformati-patologici, tipo I, sottotipo a) e b).
Ed. Travel Factory, Rome, Luglio 2009.
8. Stagnaro Sergio. There is another clinical, and overlooked tool, reliable in breast cancer prognosis evaluation , 2005. http://www.biomedcentral.com/1471-2407/5/70/comments#204473
9. Stagnaro Sergio. Bed-Side Evaluating Breast Cancer Real Risk. World Journal of Surgical Oncology. 2005, 3:67 doi:10.1186/1477-7819-3-67. 2005
10. Stagnaro Sergio Mitochondrial Bed-Side Evaluation: a new Way in the War against Cancer (21 December 2005). Cancer Cell International http://www.cancerci.com/content/5/1/34/comments#218502

11) Simone Caramel and Sergio Stagnaro (2011) Quantum Biophysical Semeiotics and mit-Genome’s fractal dimension Journal of Quantum Biophysical Semeiotics, 1 1-27, http://www.sisbq.org/uploads/5/6/8/7/5687930/joqbs_mitgenome.pdf

12) Stagnaro Sergio. A new way in the war against breast cancer, fortunately. Breast Cancer Res 2005,. http://breast-cancer research.com/content/7/2/R210/comments

13) Sergio Stagnaro and Simone Caramel. BRCA-1 and BRCA-2 mutation bedside detection and breast cancer clinical primary prevention. Front. Genet. | doi: 10.3389/fgene.2013.00039. http://www.frontiersin.org/Cancer_Genetics/10.3389/fgene.2013.00039/full [MEDLINE]

14) Sergio Stagnaro and Simone Caramel (2013). The Role of Modified Mediterranean Diet and Quantum Therapy in Oncological Primary Prevention. Bentham PG., Current Nutrition & Food Science ISSN (Print): 1573-4013; ISSN (Online): 2212-3881. VOLUME: 9, ISSUE: 1; DOI: 10.2174/1573401311309010011; http://www.benthamscience.com/contents-JCode-CNF-Vol-00000009-Iss-00000001.htm

15) Stagnaro Sergio. Non Local Realm. Response to Selection for Social Signalling Drives the Evolution of Chameleon Colour Change. (01 February 2008). http://www.plos.com, http://biology.plosjournals.org/perlserv/?request=read-response&doi=10.1371/journal.pbio.0060025

16) Stagnaro Sergio e Manzelli Paolo. Semeiotica Biofisica Quantistica: Livello di Energia libera tessutale e Realtà non locale nei Sistemi biologici. http://www.fce.it , 29 maggio 2008, http://www.fcenews.it/index.php?option=com_content&task=view&id=1421&Itemid=47

17) Stagnaro Sergio e Paolo Manzelli. L’Esperimento di Lory. Scienza e Conoscenza, N° 23, 13 Marzo 2008. http://www.scienzaeconoscenza.it//articolo.php?id=17775

18) Sergio Stagnaro. Dall’Esperimento di Lory alla Diagnostica Psicocinetica. Ruolo fondamentale della Realtà Non Locale in Biologia. http://www.fcenews.it, gennaio 2010. http://www.fceonline.it/images/docs/lory.pdf

 

La Risposta del Centers for Disease Control and Prevention (CDC) al mio Commento Critico

Ecco, dopo quella “automatica”, la prima risposta al mio commento critico, che ho appena ricevuto dalla CDC:

—- Original Message —–

From: “CDC-INFO” <CDCINFO@cdc.gov>

To: <dottsergio@semeioticabiofisica.it>

Sent: Wednesday, August 15, 2012 7:03 PM

Subject: RE: Statines against Cancer overlooking Oncological Terrai? Occasum.

Thank you for your submission to CDC-INFO about the article, Continuation With Statin Therapy and the Risk of Primary Cancer: A Population-Based Study, that you observed on the CDC website.

Your comments have been forwarded to the CDC National Center for Chronic Disease Prevention and Health Promotion for their information. They will contact you directly if they have questions.

If you have additional questions, please call 1-800-CDC-INFO, email cdcinfo@cdc.gov, or visit www.cdc.gov.
Di seguito, dopo la rapida risposta “automatica” di ricevimento del mio commento critico, la statunitense CDC mi manda oggi, Ferragosto,

CDC-INFO is a service of the Centers for Disease Control and Prevention (CDC) and the Agency for Toxic Substances and Disease Registry (ATSDR) through a contract with Vangent, Inc.

KN
[THREAD ID:2-DMCXD] [SR: 2-22878110]

—–Original Message—–

From:  dottsergio@semeioticabiofisica.it
Sent:  8/12/2012 12:18:49 AM
To:  dottsergio@semeioticabiofisica.it
Cc:  Scienza&Conoscenza <redazione@scienzaeconoscenza.it>; Volpe Roberto Prof CNR <r.volpe@spp.cnr.it>; New Engl J Med <editorial@nejm.org>; Istituto Europ Oncol Sideri Mario <mario.sideri@ieo.it>; Simone Mailing Group<sisbq_medicaldoctors@yahoogroups.com>; Giuseppe Mancia<giuseppe.mancia@unimib.it>; Mondini Alberto Libertà Cura<albertomondini@aerrepici.org>; JAMA <ama-subs@ama-assn.org>; “Di Bella Prof. Giuseppe” <posta@giuseppedibella.it>; Federaz Argent Cardiol<info-pcvc@fac.org.ar>; Diabetologia Editors <diabetologia-j@bristol.ac.uk>; Lancet Editors <Editorial@lancet.com>; Marianna De Palma<mari_madeche@hotmail.com>; BMC Editors <editorial@biomedcentral.com>; Medico d’Italia Bernardini <numedi@tiscalinet.it>; “ATHERO .org” <info@athero.org>; De Magistris Prof Roberto a <RDEMA@UNINA2.IT>; Altro Giornale<pasgal@gmail.com>; Ann Int Med Editors <annp@mail.acponline.org>; <redazione@ilsecoloXIX.it>; <info.roma@fondazioneveronesi.it>; <umbert.veronesi@ieo.it>; <silvio.garattini@marionegri.it>; <mnegri@marionegri.it>; <asco@asco.org>; <jcoservice@asco.org>; <jopcontact@asco.org>; <contactus@cancer.net>
Subject:  Statines against Cancer overlooking Oncological Terrai? Occasum.
To Centers for Disease Control and Prevention, and to ALL, especially to Elyse Blye, ASCO Senior Editorial Assistant,
the article published on Journal current issue, “Continuation With Statin Therapy and the Risk of Primary Cancer: A Population-Based Study,  “Miriam Lutski, et al., Prev Chronic Dis 2012;9:120005. DOI: http://dx.doi.org/10.5888/pcd9.120005, though considered worthy of Medscape CME…, is fundamentally based since it is no up-dated.

In fact, neither Authors, nor CDC Editors, and Reviewers – not to speak of Medscape friends, of course  –  seemingly ignore, perhaps overlook,  Oncological Terrain-Dependent, Inherited Real Risk, beside recognised, i.e., with a simple stethoscope, and healed with BLUE THERAPY www.sisbq.org  and  www.semeioticabiofisica.it.

Really, based on a long-well-established experience, you may read in above websites Bibliography, individuals not involved by such a predisposition to cancer, characterised by microcirculatory remodelling, showing typical newborn-pathological, type I, subtype a) ONCOLOGICAL, Endoarteriolar Blocking Devices in arterioles and small artery, accordinf to Hammersen, due to the lowering of fractal dimension of both mit-DNA and n-DNA in parenchimal cells, according to my  Angiobiopathy Theory,  where the cancer can occur, will never suffer fron MALIGNCY, independently of using or not STATINE and  smoking tobacco!

At this point, I emphasise the severe, dangerous  muscle disorder – deadly rabdomyolysis – brought about by statine assumption by individual suffering from NO-Recognised  Co Q 10 Deficiency Syndrome (Stagnaro-Neri M., Stagnaro S., Sindrome clinica percusso-ascoltatoria da carenza di Co Q10. Medic. Geriatr. XXIV, 239, 1993), I have denounced 12 years before CERIVASTATINE bad story:
Stagnaro-Neri M., Stagnaro S., Carenza di Co Q10 secondaria a terapia ipolipidemizante diagnosticata con la Percussione Ascoltata. Settimana Italiana di Dietologia, 9-13 Aprile 1991, Merano. Atti, pg. 65. Epat. 37, 17, 1990.

Finally, I think that  the time has come to re-evaluate the greatest “economic” enterprise, i.e., FRAMINGHAM HEART STUDY, at the light of Quantum Biophysical Semeiotics results:

Sergio Stagnaro. Without CAD Inherited Real Risk, All Environmental Risk Factors of CAD are innocent Bystanders. Canadian Medical Association Journal. CMAJ, 14 Dec 2009,  http://www.cmaj.ca/content/181/12/E267/reply

Stagnaro Sergio.    CAD Inherited Real Risk, Based on Newborn-Pathological, Type I, Subtype B, Aspecific, Coronary Endoarteriolar Blocking Devices. Diagnostic Role of Myocardial Oxygenation and Biophysical-Semeiotic Preconditioning.International Atherosclerosis Society. www.athero.org, 29 April, 2009  http://www.athero.org/commentaries/comm907.asp

Stagnaro Sergio. Role of Coronary Endoarterial Blocking Devices in Myocardial Preconditioning – c007i. Lecture, V Virtual International Congress of Cardiology, 2007. http://www.fac.org.ar/qcvc/llave/c007i/stagnaros.php

Do you agree with me, don’t you?

I appreciate your critical answer.

Regards,

Sergio Stagnaro MD
Via Erasmo Piaggio 23/8,
16039 Riva Trigoso (Genoa) Italy
Ph 0039-0185-42315
Cell. 3338631439
www.semeioticabiofisica.it
www.sisbq.org
dottsergio@semeioticabiofisica.it

In attesa di seguire gli eventi, con piacere noto che gli statunitensi non sono intollerant alle critiche come i “Professori” italiani, che non rispondono oppure respingono le mie mail, come fossero spam!

Conservo alcune mail di “Professori”, tra loro anche sedicenti “CATTOLICI”, che mi invitano, assai infastiditi, a non scrivere più mail indirizzate a loro.

Nel commento, ancora una volta,  trovate il mio J’accuse:  “I think that  the time has come to re-evaluate the greatest “economic” enterprise, i.e., FRAMINGHAM HEART STUDY, at the light of Quantum Biophysical Semeiotics results”.

To be continued!

Donna Summer Muore di Cancro a 63 anni. Ai Posteri la prevista Sentenza?

Da Il Secolo XIX del 17 maggio 2012. È morta Donna Summer.  http://www.ilsecoloxix.it/p/cultura/2012/05/17/APrniIXC-morta_donna_summer.shtml#axzz1uurqrnHy:

“Genova – Donna Summer, la regina della disco music, è morta questa mattina dopo una lunga battaglia contro il cancro al polmone che lei sosteneva di aver contratto inalando sostanze tossiche”.

L’inalazione di cancerogeni – come il fumo di tabacco – “provoca” il cancro secondo una visione  superata dell’Oncolgogia, tipica della presente Era dei Lumi Spenti.

Povera Donna Summer; attribuiva il cancro del polmone all’inalazione dei sostanze tossiche,  perché evidentemente qualche amico suo,  laureato in Medicina, le aveva suggerito  questo delirio scientifico, che appaga la falsa coscienza dello scienziato non aggiornato.

Fino a quando i medici, in generale, e gli oncologi e i “Professori” , in particolare, continueranno ad ignorare il Terreno Oncologico e il Reale Rischio Oncologico, Dipendente dal Terreno Oncologico, ben localizzabile con un fonendoscopio e GUARIBILE con semplice terapia non costosa, www.sisbq.org,  i giornalisti continueranno a scrivere articoli strappa-lacrime, gli oncologi proseguiranno nelle loro mass-mediatiche deliranti esternazioni,  la TV ci donerà riprese commoventi di funzioni religiose, e la gente comune applaudirà ai funerali (1-10).

Un Ente latente  oggi è il Pensiero: sembra che, ormai abituato solo a parlare, l’uomo del terzo Millennio non pensa più.

Nemmeno risponde alle mail ricevute, magari per semplice educazione. Per esempio, alla mia Lettera Aperta al Prof. Umberto Veronesi.   Dieci Domande: eccetera, V. URL https://sergiostagnaro.wordpress.com/wp-admin/post.php?post=425&action=edit, NON è stata data finora risposta.

Prepariamo gli applausi per il  prossimo funerale!

Lettura Consigliata:

1)    Stagnaro-Neri M., Stagnaro S., Acidi grassi Omega-3, scavengers dei radicali liberi e attivatori del ciclo Q e della sintesi del Co Q10. Gazz. Med. It. – Arch. Sc. Med. 151, 341,1992 (MEDLINE).

2)    Stagnaro Sergio, Stagnaro-Neri Marina. Introduzione alla Semeiotica Biofisica. Il Terreno oncologico”. Travel Factory SRL., Roma, 2004.

3)    Stagnaro S., Stagnaro-Neri M., Le Costituzioni Semeiotico-Biofisiche.Strumento clinico fondamentale per la prevenzione primaria e la definizione della Single Patient Based Medicine. Ediz. Travel Factory, Roma, 2004.

4)    Stagnaro Sergio. Bed-Side Prostate Cancer Detecting, even in early stages (“Real Risk” of Cancer): BMC Family Practice, 6:24 doi:10.1186/1471-2296-6-24 http://www.biomedcentral.com/1471-2296/6/24/comments#202466

5)    Sergio Stagnaro Mitochondrial Bed-Side Evaluation: a new Way in the War against Cancer (21 December 2005). Cancer Cell International http://www.cancerci.com/content/5/1/34/comments#218502

6)    Stagnaro S. Genes and Cancer: a clinical view-point. The Oncological Terrain. BioMed Central Informatics, 2004. http://www.biomedcentral.com/1471-2105/5/21/comments#10454

7)    Stagnaro S., Stagnaro-Neri M., Oncological Terrain, conditio sine qua non of Oncogenesis, GUT, 2004. http://www.gutjnl.com/cgi/eletters?lookup=by_date&days=60

8)    Stagnaro Sergio. “Genes, Oncological Terrain, and Breast Cancer”, World Journal of Surgical Oncology. 2005, http://www.wjso.com/content/3/1/45/comments#205475

9)    Stagnaro Sergio. GPs , Biophysical Semeiotics, and bedside cancer diagnosis. 08 July 2007, International Seminar of Surgical Oncology, http://www.issoonline.com/content/4/1/11/comments#281539

10)                      Stagnaro Sergio. Overloking Oncological Terrain and oncological Real Risk, no paper is up-dated! 18 January 2008 Ann. Intern Med. http://www.annals.org/cgi/eletters/147/11/775

11)                      Stagnaro Sergio. Reale Rischio Semeiotico Biofisico. I Dispositivi Endoarteriolari di Blocco neoformati, patologici, tipo I, sottotipo a) oncologico, e b) aspecifico. Ediz. Travel Factory, www.travelfactory.it, Roma, 2009.

12)                      Caramel S., Stagnaro S. L’importanza dei mitocondri  e del mit-DNA nell’Oncogenesi.  http://ilfattorec.altervista.org/mitDNAoncogenesi.pdf;

to be continued …..

 

Breast Cancer Defeated by Quantum Biophysical Semeiotics, the “Professors” not yet!

In following, I  illustrate  Bedside Detecting  Oncological Terrain-Dependent, Inherited Real Risk of Breast Cancer, which  plays a central Role in its Primary Prevention by means of no expensive therapy,  and thus we are able to defeat breast cancer, if we wont it, of course.

In spite of thousand peer reviews and million of paramount articles and Editorials,  Cancer, including Breast Cancer,  is today’s growing EPIDEMIC all around the world.

As a consequence, there is somethink wrong regarding the so-called epochal advances of international Oncology.

Aiming to lower the number of negative biopsies, and especially  aiming to avoid  useles breast biopsy, causing Psychological Jatrogenetic Terrorism (1), physicians have to familiarise with the concept of Oncological Terrain, as well as OT-Dependent, Inherited Real Risk (1-12), obtaining  the best   results in the war against breast cancer (2-7).

There is a general agreement that Primary, and especially Pre-Pimary Prevention http://www.sisbq.org/qbs-magazine.html, ignored unfortunately by “Professors”, is far better than every therapy

At this point, I emphasise that, even the surgical operation, the only efficacious tool in removing an “initial” small cancer,  cannot eliminate Oncological Terrain and possible OT-dependent, Inherited Real Risk!

Based on 55 year-long, well-established clinical experience, for all women (and men, too!), an original clinical assessment, unavoidable also to breast biopsy,  proved to be useful and reliable, applied easily, and quickly, allowing to bedside recognize the presence of maternally-inherited, functional mitochondrial cytopathy, termed Congenital Acidosic-Enzyme Metabolic Histangiopathy, Oncological Terrain, conditio sine qua non of cancer, is based on (1-10).

In fact, it is sufficient ascertaining breast cancer Oncological Terrain-Dependent, Inherited Real Risk, i.e., local microcirculatory remodelling,  localized in well-defined breast quadrant(s), and characterized by newborn-pathological, type I, subtype a) oncological, Endoarteriolar Blocking Devices (8, 9).

In addition, testing for mutations of breast cancer susceptibility genes or for their diminished expression adds to our ability to assess breast cancer risk at an individual level. Really, we cannot localise in one, or more, mamma quadrant the possible breast cancer risk in BRCA 1 and BRCA 2, as well as a lot of other gene mutations-positive women (and men!).

Quantum Biophysical Semeiotics (http://www.semeioticabiofisica.it, Breast Cancer in Practical Application; Oncological Terrain, and www.sisbq.org) allows doctor to recognize firstly oncological terrain  in a quantitative way, and then, but “not” in all cases, of course, breast cancer inherited real risk. As a matter of fact, individuals with oncological terrain do not show generally real risk in all biological systems (3). Interestingly, the absence of both Oncological Terrain and breast oncological “Inherited Real Risk”, the later in a subject with Oncological Terrain, excludes beyond every doubt the possibility of occurrence of breast cancer (2, 3-8). As a consequence, we can perform nowadays an efficacious clinical, primary prevention of breast cancer (4), on very large scale, based on the Single Patient Based Medicine (5, 10).

Finally, “real” sentinel lymphonodes are trigger-points for autoimmune syndrome, bedside diagnosed in a few seconds (3, 4)

Regarding the healing of  Oncological Terrain-Dependent Inherited Real Risk, I invite the readers to visit above-mentioned websites.

In a few words, under Mediterranean modified Diet (a paper in press by Bentham Current Nutrition & Food Science) , etymologically speaking, Melatonin-Coniugated, according to Di Bella – Ferrari (or other efficient Melatonin), Thermal Sulfidrilic Water (I have studied the water of “La Puzzola, Porretta Terme, Bologna); a unique application of Cem Tech a russish quantum-devices, Oncological Terrain and Oncological Inherited Real Risk disappear, allowing me to state that Breast Cancer is defeated by Quantum Biophysical Semeiotics, the “Professors” not yet!

References
1) Stagnaro Sergio, Stagnaro-Neri Marina. Introduzione alla Semeiotica Biofisica. Il Terreno oncologico. Travel Factory SRL., Roma, 2004.

http://www.travelfactory.it/semeiotica_biofisica.htm

2) Stagnaro Sergio.   Overloking Oncological Terrain and oncological Real Risk, no paper is up-dated!  18 January 2008, Annals of Internal Medicine  http://www.annals.org/cgi/eletters/147/11/775

3)  Stagnaro Sergio.  There is another clinical, and overlooked tool, reliable in breast cancer prognosis evaluation, BioMed Central, 2005.  http://www.biomedcentral.com/1471-2407/5/70/comments#204473

4) Stagnaro-Neri M., Stagnaro S. Cancro della mammella: : prevenzione primaria e diagnosi precoce con la percussione ascoltata. Gazz. Med. It.; Arch.  Sc.  Med. 152, 447, 1993.
5)  Stagnaro Sergio. A new way in the war against breast cancer, fortunately.

 Breast Cancer Res 2005,. http://breast-cancer research.com/content/7/2/R210/comments
4)  Stagnaro Sergio.    Rinaldi’s Sign in bedside Diagnosing   Di Bella’s Oncological Terrain, and overt Cancer, solid and liquid. Lectio Magistralis, II Convegno Nazionale della SISBQ, Chiusi (Siena), 28-29 maggio 2011. http://www.sisbq.org/acts-of-the-second-conference.html

http://www.sisbq.org/uploads/5/6/8/7/5687930/rinaldisign_eng.pdf

5) Stagnaro S., Stagnaro-Neri M. Single Patient Based Medicine. La Medicina Basata sul Singolo Paziente: Nuove Indicazioni della Melatonina. Travel Factory SRL., Roma, 2005. http://www.travelfactory.it/semeiotica_biofisica.htm

6) Stagnaro Sergio.  “Genes, Oncological Terrain, and Breast Cancer”.  World Journal of  Surgical Oncology., 2005, http://www.wjso.com/content/3/1/45/comments#205475

7) Stagnaro  Sergio Mitochondrial Bed-Side Evaluation: a new Way in the War against Cancer (21 December 2005). Cancer Cell International  http://www.cancerci.com/content/5/1/34/comments#218502

8) Stagnaro Sergio. Reale Rischio Semeiotico Biofisico. I Dispositivi Endoarteriolari di Blocco neoformati, patologici, tipo I, sottotipo a) oncologico, e b) aspecifico. Ediz. Travel Factory, www.travelfactory.it, Roma, 2009.

9) Caramel S., Stagnaro S. The role of mitochondria and mit-DNA in Oncogenesis. http://ilfattorec.altervista.org/mitDNA&oncogenesis_english.pdfQuantum Biosystems 2010, 2, 221-248

 

10) Stagnaro Sergio. Quantum biophysical semeiotics. NeuroQuantology | September 2011 | Vol 9 | Issue 3 | Page 459‐467. http://www.neuroquantology.com/index.php/journal/issue/current/showToc

 

11) Sergio Stagnaro and Simone Caramel (2011). The genetic Reversibility in Oncology, Journal of Quantum Biophysical Semeiotics, http://www.sisbq.org/uploads/5/6/8/7/5687930/reverse_oncology.pdf

12) Sergio Stagnaro.  Oncological Terrian’s Paramount Role in Fighting Cancer . 2012 MENA Health World, January 2012, Vol. 1, Pg 16. http://www.mhwmag.net/levelthree.aspx?magazine_subsection_id=3047&all_lk_id=252&magazine_section_id=1&magazine_id=4

Veramente c’è la Volontà di Prevenire il Cancro Colonrettale?

Di seguito un Comment inviato ad Annals of Internal Medicine a proposito di un articolo, dal titolo “Screening for Colorectal Cancer: A Guidance Statement From the American College of Physicians”,  in rete alla URL http://www.annals.org/content/156/5/378.abstract?aimhp

Lo divulgo perché è interessante per la Prevenzione Primaria del Cancro Colorettale, non perché DUBITI che gli Editori di Ann Int Med. non lo metterannoin rete ………

Overlooking Oncological Terrain-Dependent Inherited Real Risk of Colorectal Cancer, no Primary Prevention is efficacious.

Quantum Biophysical Semeiotics Laboratory

In cancer Primary Prevention,including colorectal cancer (1), doctors around the world need a clinical tool that helps them in bed side recognizing,starting from the birth, on very large scale and in apparently healthy individuals, genetical errors, e.g., hyperinsulinemia- insulinresistance, melatonine and SST deficiency, metabolic disorders, prevalence of stress axis, a.s.o., which either bring about or aggravate n -DNA as well as mit-DNA alterations, as those observed in cancer cells(1- 8). In fact, our target, i.e., colorectal cancer primary prevention surely better than cancer screening, can be reached hopefully if doctors are able to ascertain or at least suspect at the bed-side in apparently healthy subjects chromosomal aberrations before malignancy on-set (1-12). In other words, physicians must recognize and quantify clinically both Oncological Terrain and inherited colorectal cancer Real Risk, based on newborne- pathological, type I, subtype a), oncological, colon endoarteriolar Blocking Devices (See http://www.semeioticabiofisica.it/microangiology, Physiology and Pathology) (2-8). As a working hypothesis, I thought previously that all chromosomal alterations, of whatever nature, are necessarily accompanied with similar microvascular modification of the local microcirculatory bed, both structural and functional in nature, in subject involved by abnormalities of pschyco-neuro-endocrinological-immune system (6). As a matter of fact, both genetical and environmental factors induce contemporaneously parenchymal and microvascular cells alterations, according to the well-known concept of Tiscedorf’s Angiobiotopie, I completed with that of Angiobiopathy (6). As a consequence, in all researches on colorectal cancer primary prevention, we must enrolle exclusively individuals positive for Oncological Terrain AND inherited colorectal cancer Real Risk, conditio sine qua non of oncogenesis. Now, fortunately, thanks to Biophysical Semeiotics (ibidem), we can evaluate clinically microcirculatory bed structure and function in a precise manner and therefore microcirculatory remodelling, oncological inherited Real Risk is based on (6-12). My 51-year-long “clinical” experience allows me to state that the decline in cancer rates all over the world could be more intense when scientists will think over and discuss the possibility that exists the Oncological Terrain and Inherited Oncological Real Risk, conditio sine qua non of oncogenesis (9-12). As a matter of fact, e.g., not all smokers are involved by pulmonary cancer, as well as not all people with chronic hepatitis will die of hepatocarcinoma. On the other side, in some families malignancies occur more frequently than in others. Actually, as I described in the above-mentioned papers, there are other causes that accounts for the reason of existence of the oncological “real” risk, i.e. oncological terrain. From the above remarks, the following critical comment is really useful:

Guidance Statement 1 ACP recommends that clinicians perform individualized assessment of risk for colorectal cancer in all adults….. involved by Oncological Terrain-Dependent Inherited Real Risk of colorectal cancer!

Guidance Statement 2 ACP recommends that clinicians screen for colorectal cancer in average-risk adults starting at the age of 50 years and in high-risk adults starting at the age of 40 years or 10 years younger. Not at all. We are able to bedside evaluate Oncological Terrain- Dependent Inherited Real Risk of colorectal cancer, and its evolution, possible also in younger!

Guidance Statement 3: ACP recommends using a stool-based test, flexible sigmoidoscopy, or optical colonoscopy as a screening test in patients who are at average risk. Not at all. We must use these diagnostic tools when and if necessary, according to above cited data of physical examination!

Guidance Statement 4: ACP recommends that clinicians stop screening for colorectal cancer in adults over the age of 75 years or in adults with a life expectancy of less than 10 years. Not at all. If I, 80 year-old, woul be involved by Oncological Terrain-Dependent Inherited Real Risk of colorectal cancer or cancer I would need the most up-dated therapy!

References.

1)Sergio Stagnaro. Stagnaro’s *Sign in detecting every gastrointestinal Disorder, even initial or symptomless. Journal of Quantum Biophysical Semeiotics. 28 July, 2011. http://www.sisbq.org/uploads/5/6/8/7/5687930/stagnarosign.pdf 2) Stagnaro-Neri M., Stagnaro S., Semeiotica Biofisica del torace, della circolazione ematica e dell’anticorpopoiesi acuta e cronica. Acta Med. Medit. 13, 25 1997 3) Stagnaro-Neri M., Stagnaro S., Semeiotica Biofisica: la manovra di Ferrero-Marigo nella diagnosi clinica della iperinsulinemia-insulino resistenza. Acta Med. Medit. 13, 125 1997 4) Stagnaro-Neri M., Stagnaro S., Semeiotica Biofisica: valutazione clinica del picco precoce della secrezione insulinica di base e dopo stimolazione tiroidea, surrenalica, con glucagone endogeno e dopo attivazione del sistema renina-angiotesina circolante e tessutale – Acta Med. Medit. 13, 99. 5) Stagnaro S., Sindrome percusso-ascoltatoria di Iperfunzione del Sistema Reticolo-Istiocitario. Min. Med. 74, 479, 1983 (Medline) 6) Stagnaro-Neri M., Stagnaro S. Introduzione alla Semeiotica Biofisica. Il Terreno Oncologico. Travel Factory, Roma, 2004. http://www.travelfactory.it 7) Stagnaro Sergio. Reale Rischio Semeiotico Biofisico. I Dispositivi Endoarteriolari di Blocco neoformati, patologici, tipo I, sottotipo a) oncologico, e b) aspecifico. Ediz. Travel Factory, http://www.travelfactory.it, Roma, 2009. 8) Stagnaro S. Rimodellamento Microvascolare, Costituzioni Semeiotico- Biofisiche e Reale Rischio Semeiotico-Biofisico. Ruolo dei Dispositivi Endoarteriolari di Blocco neoformati-patologici http://www.clicmedicina.it, 10/4/2007, http://www.clicmedicina.it/pagine%20n%2028/rimodellamento.htm 9) Sergio Stagnaro and Simone Caramel (2011). The genetic Reversibility in Oncology, Journal of Quantum Biophysical Semeiotics, http://www.sisbq.org/uploads/5/6/8/7/5687930/reverse_oncology.pdf

10) Stagnaro S., Stagnaro-Neri M., Oncological Terrain, conditio sine qua non of Oncogenesis, 2004: http://www.gutjnl.com/cgi/eletters?lookup=by_date&days=60 11) Stagnaro S. Cancer Risk Factors and Oncological Terrain. 2006. http://www.wjso.com/content/4/1/74/comments#247528 12) Sergio Stagnaro and Simone Caramel (2012) New ways in physical Diagnostics: Brain Sensor Bedside Evaluation. The Gandolfo’s Sign. January, 2012. Journal of Quantum Biophysical Semeiotics. http://www.sisbq.org/uploads/5/6/8/7/5687930/bsbe.pdf

Tag Cloud